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ABSTRACT OF THESIS

THE BEHAVIORAL EFFECTS OF FIRST-GENERATION ELECTRONIC
CIGARETTES AFTER 24-HOUR TOBACCO DEPRIVATION
Little is currently known about the ability of electronic cigarettes to manage
tobacco withdrawal symptoms and their abuse liability. In the current study eight
conventional cigarette smokers completed nine within-subject study sessions. In the first
session participants practiced using an electronic cigarette containing 16 mg/ml of
nicotine over six 10-puff bouts. Remaining study sessions were comprised of four twoday blocks (one for each condition), which assessed measures of tobacco withdrawal
symptoms and abuse liability following unrestricted cigarette smoking and 24-hour
tobacco deprivation. Study conditions included an electronic cigarette with 0, 8, or 16
mg/ml nicotine concentrations, or preferred brand of conventional cigarette. Following
24-hours of tobacco deprivation, smoking conventional cigarettes ameliorated many of
the self-report and physiological symptoms (decreased heart rate) associated with tobacco
deprivation, while no attenuation of withdrawal symptoms was indicated following using
electronic cigarettes, independent of nicotine dose. On abuse liability measures there
were no significant changes following using an electronic cigarette (regardless of nicotine
concentration), while conventional cigarettes engendered significant changes on abuse
liability measures. Within the conditions of this study, first-generation electronic
cigarettes had no measurable efficacy in ameliorating tobacco withdrawal symptoms and
a reduced abuse liability compared to conventional tobacco cigarettes.
KEYWORDS: Abuse liability, smoking, tobacco cessation, nicotine, withdrawal
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CHAPTER ONE: INTRODUCTION TO ELECTRONIC CIGARETTES
History and Definition
For decades attempts have been made to develop a nicotine-delivery device that
provides stimuli similar to that of a tobacco cigarette without the negative aspects of
inhaling tobacco smoke. One of the earliest examples of such an attempt can be found in
a patent filed in 1963 (Gilbert, 1965), which proposed a device that could “provide a safe
and harmless means for and method of smoking by replacing burning tobacco and paper
with heated, moist, flavored air.” Despite this patent, no serious attempt to manufacture
and distribute such a device was made. It was not until years later that trials began on
devices that delivered nicotine via inhalation. In 1979, Jacobson and colleagues (1979)
published data demonstrating that serum nicotine levels comparable to those delivered by
conventional tobacco cigarettes (CC) could be obtained by using a “non-combustible
cigarette.” This device did not use combustion or electricity but rather passive diffusion
of nicotine, embedded in filter paper, into the air as the user inhaled (Dunworth, 2014).
For a short while this device was manufactured and distributed under the name “Favor,”
but ultimately failed due to a short shelf life caused by rapid degradation of nicotine into
a bitter tasting metabolite, cotinine (Dunworth, 2014). During the 1980’s the major
tobacco manufacturer R.J. Reynolds was attempting to develop a CC alternative. While
R.J. Reynolds filed numerous patents that outlined devices practically indistinguishable
from current EC’s (e.g. Brooks, Roberts, and Simmons, 1990), no major attempts to
distribute and manufacture such a device are documented. The invention of the modern
EC has been attributed to Chinese pharmacist Hon Lik, who filed a patent in 2004 for a
“flameless electronic atomizing cigarette” (Lik, 2006). This patent outlines an
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electronically powered device that vaporizes a mixture containing, among other things,
nicotine, glycerol, propylene glycol, and water with an electro-thermal vaporization
nozzle. Most modern EC’s still adhere to these basic ingredients and mechanics.
Although there are similar mechanics and ingredients between EC’s, there are
many variations in modern EC’s that must be identified when discussing EC’s. As of
January 2014, it was estimated that there were at least 466 different brands of electronic
cigarettes and 7,764 different flavors (Zhu et al., 2014). Amidst this large variety of
options, three separable categories of EC’s have emerged: first-, second-, and thirdgeneration EC’s (Zhu et al., 2014). First generation EC’s, colloquially referred to as
“cig-a-likes,” are similar to CC’s in appearance and have relatively low-capacity
batteries, non-refillable liquid cartridges, few (if any) variable settings, and operate at
lower wattages. First generation EC’s typically come in disposable (the entire device is
discarded once the battery has been depleted or the liquid is gone) or rechargeable (nonrefillable liquid cartridges and the battery can be recharged) variants. Second-generation
devices, also known as “eGo” devices, are relatively larger than first-generation devices
and typically have larger rechargeable batteries, refillable liquid tanks, and some user
adjustable parameters (e.g. variable voltage). Third-generation devices, also called
“mods,” typically have many user-customizable parameters (e.g. voltage or wattage) and
configurations (e.g. different types of tanks or batteries), and some variants can operate at
power levels of 100 watts or more.
Prevalence of Electronic Cigarette Use
Since the introduction of the modern EC about a decade ago, EC use (vaping) has
been quickly increasing worldwide. In the United Kingdom, EC use more than doubled

2

(from 2.7% to 6.7%) between 2010 and 2012 (Dockrell et al., 2013). Among CC
smokers in the Czech Republic in 2012, 50% had tried EC’s, while 18.3% used EC’s
regularly (Kralikova et al., 2013), with 23.5% having ever used an EC and 8.2% having
used an EC in the past 30 days (Goniewicz and Zielinska-Danch, 2012). Among men in
Switzerland between 2010 and 2013, despite a ban on sale of nicotine containing EC’s,
4.9% had used an EC in the last 12-months (Douptcheva et al., 2013). Among CC
smokers in the United States, United Kingdom, Canada, and Australia between 2010 and
2011, 7.6% had tried EC’s, while 2.9% were current users (Adkison et al., 2013). In the
United States the percentage of individuals who were aware of EC’s doubled (from
16.4% to 32.2%) between 2009 and 2010, while the percentage of individuals who had
tried EC’s quadrupled (from 0.6% to 2.7%) between 2009 and 2010 (Regan et al., 2013).
Among young-adults (ages 18-25 years) in the United States who had reported some
cigarette use (at least once per month), past-month EC use had increased from 6% in
2009-2010 to 41% in 2013 (Ramo, Young-Wolff, and Prochaska, 2015). This literature
yields widely disparate prevalence estimates of EC use, which likely reflects the rapid
growth of EC use by region and time. Nonetheless, there is converging evidence for a
steadily increasing rate of EC use, which underscores the need for further information on
the behavioral effects of these devices.
Electronic Cigarettes and Tobacco Withdrawal Symptoms
Although the health effects of EC’s have not been fully characterized, leaving
questions about potentially negative effects on the users health (e.g. Goniewicz et al.,
2014), it has been argued that EC’s could be used as a harm reduction tool for current CC
smokers (for review see Farsalinos and Polosa, 2014). Although evidence showing
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efficacy of EC’s as smoking cessation devices is limited, a recent meta-analysis has
shown that EC use is associated with a reduction in CC smoking (Rahman et al., 2015).
As a smoking cessation tool, EC’s might be able to diminish CC smoking withdrawal
symptoms and reduce smoking relapse rates among individuals who are current CC
smokers.
The withdrawal effects of CC’s have been well characterized. Tobacco
withdrawal has been generally defined as “a syndrome of behavioral, affective, cognitive,
and physiological symptoms, typically transient, emerging upon cessation or reduction of
tobacco use, and causing distress or impairment” (Shiffman, West, and Gilbert, 2004).
Within 24-hours of abstinence from tobacco, individuals typically report increased levels
of craving for tobacco, increase in negative affective states (e.g. feeling angry, impatient,
anxious, or depressed) (Hughes, 2006; Piper et al., 2011), impaired cognition (Heishman,
Taylor, and Henningfield, 1994; Shiffman, West, and Gilbert, 2004; Swan and LessovSchlaggar, 2007; Heishman et al., 2010), and decreased heart rate (Hughes, 1992). To
date, there are only a small number of laboratory studies that have examined the ability of
EC’s to alleviate the aforementioned withdrawal symptoms. In a study by Bullen and
colleagues (2010), following a 12-hour tobacco deprivation period, EC naïve CC smokers
were allowed ad libitum access to a first-generation EC with 0 or 16 mg/ml nicotine
concentration. Following using an EC with 0 or 16 mg/ml nicotine concentrations,
participants reported reductions in negative affective states (i.e. irritability, restlessness,
and difficulty concentrating) and cravings to smoke independent of nicotine
concentrations, but to a lesser degree than following smoking a CC. In a study by
Vansickel and colleagues (2010), EC naïve CC smokers who refrained from smoking for
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12 hours administered 10-puffs from first-generation EC’s that contained liquid with 16
or 18 mg/ml nicotine concentration, which significantly reduced cravings for smoking
compared to baseline, though the reductions in cravings were less than those following
smoking a CC. In another study by Vansickel and colleagues (2012), following a 12hour tobacco deprivation period, EC naïve CC smokers administered six 10-puff bouts
from a first-generation EC with 18 mg/ml nicotine concentration with 30-minutes
between bouts, after which increases in heart rate and decreases in reported craving for
smoking and negative affective states (e.g. anxiousness, restlessness, and
irritability/frustration/anger) were reported. In a third study by Vansickel and Eissenberg
(2013), regular EC users with minimal current CC use (< 5 cigarettes/day) administered
10-puffs from their own EC’s (typically containing 18 mg/ml nicotine concentration)
following a 12 hour EC and CC deprivation period. After administration of 10-puffs
there were decreases in negative affective states (i.e. “anxious,” “restlessness”), cravings
for smoking and intentions to smoke, and an increase in heart rate relative to levels prior
to EC use. In a study by Dawkins and colleagues (2012), following a 1-hour CC
deprivation period, EC naïve CC smokers used a first-generation EC containing 0 or 16
mg/ml nicotine concentration ad libitum for a five-minute period. Following EC use,
there were decreases in some negative affective states (contingent upon being male or
female) in both 0 and 16 mg/ml nicotine concentration conditions vs. just holding an EC.
Similarly, there were mixed effects on cognitive functioning with individuals in the 0
mg/ml condition making fewer errors on an attention task relative to individuals who just
held an EC, and individuals in the 16 mg/ml condition making fewer recall errors on a
memory task compared to individuals who just held an EC. In another study by Dawkins
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and colleagues (2013), following 12-hours of tobacco deprivation, CC smokers used a
second-generation EC containing 0 or 16 mg/ml nicotine concentration ad-libitum for 10
minutes. Compared to the 0 mg/ml condition, individuals performed better on a
prospective memory task and reported greater reductions in negative affective state (i.e.
anxiousness) and cravings to smoke after using an EC with 16 mg/ml nicotine
concentration. In a study by Yan and D’Ruiz (2015), following 36-hours of tobacco
deprivation regular CC smokers took 50-puffs from a first-generation EC containing 16
or 24 mg/ml nicotine concentration, followed by ad-libitum EC use for one hour. After
taking 50-puffs and ad-libitum EC use, dose-related increases in heart rate were shown
following EC use, with increases after using an EC with 24 mg/ml nicotine
concentrations that were comparable to increases following smoking a CC. In a study by
Lechner and colleagues (2015), following a 12-hour tobacco deprivation period regular
CC smokers with minimal EC use were given five minutes of ad-libitum access to a firstor second-generation EC containing 16 mg/ml nicotine concentration. Following use,
both first- and second-generation EC’s reduced negative affective states and cravings to
smoke, with greater reductions following second-generation EC’s compared to firstgeneration EC’s. Using a slightly different design than the previous studies, Norton and
colleagues (2014) allowed a group of regular CC smokers to use a first-generation EC
with 11 mg/ml nicotine concentration in lieu of a CC over a 72-hour period. After the
72-hour period, withdrawal symptoms were not significantly different than baseline
levels. It is difficult, however, to interpret this finding because many individuals in this
study did not successfully abstain from CC use during the 72-hour period, and there were
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no other comparison conditions during the 72-hour period (e.g. abstinence from EC or
CC use).
The aforementioned studies suggest that EC’s can ameliorate some CC
withdrawal symptoms, but typically to a lesser extent than CC’s. Yet, there are several
limitations to these studies that make interpreting their results difficult. One limitation is
that all but one (Norton et al., 2014) of the previous studies did not collect predeprivation levels of the withdrawal symptoms and only collected measures immediately
prior to using an EC. While previous characterizations of withdrawal can help to identify
typical withdrawal symptoms, pre-deprivation measurements are required to validate the
presence of a true withdrawal symptom. In recognition of this problem, Shiffman and
colleagues (2004) suggest that stable baseline levels of candidate withdrawal symptoms
be collected across multiple sessions, following unrestricted smoking, in order to obtain
stable baseline levels of withdrawal symptoms. Then, pre-deprivation measurements can
be used to determine true withdrawal symptoms as those that have changed relative to
baseline levels following a deprivation period.
There is ambiguity in the literature as to when exactly tobacco withdrawal
symptoms emerge. Most studies that have examined tobacco withdrawal symptoms have
assessed post-smoking levels 24-hours or more since the beginning of tobacco
deprivation (for review see Hughes, 2006). Thus, it is unclear when exactly withdrawal
symptoms begin within 24-hours of tobacco deprivation. There is, however, evidence
that some withdrawal symptoms (e.g. craving for smoking and heart rate) begin to
manifest within 30 minutes following smoking (Hendricks et al., 2006). This might
suggest that the ideal time to measure craving for smoking is immediately following the
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last tobacco administration preceding a tobacco deprivation period. Yet, on other
measures, acute smoking effects could confound measurements taken immediately after
smoking. For example, there are well-characterized acute smoking effects on cognitive
performance measures (Heishman, Kleykamp, and Singleton, 2010). Additionally, it has
been shown that some self-report measures of tobacco withdrawal symptoms (e.g.
difficulty concentrating, anxiety, sadness) do not begin to appear until at least 30-minutes
following smoking (Hendricks et al., 2006). In recognition of the ambiguity of
withdrawal symptom time course, measures in the current study were collected following
ad libitum smoking conditions and immediately following smoking on baseline days.
These data were used to help interpret the effects of smoking conditions on performance
following tobacco deprivation.
Another limitation in the literature on alleviation of tobacco withdrawal
symptoms by EC’s is that none of the aforementioned studies examined different
concentrations of nicotine within the same device, and selected only one nicotine
concentration and compared it to an EC with 0 mg/ml. Thus, it remains uncertain
whether there is a dose-dependent relationship between nicotine concentration in EC’s
and their ability to ameliorate tobacco withdrawal symptoms. A final limitation is that
the aforementioned studies typically used short deprivation periods (e.g. 1-12 hours of
deprivation from tobacco). Although some tobacco withdrawal symptoms may occur
soon after smoking, some may take longer to develop (as discussed in Hughes, 1992).
Therefore, a longer period of tobacco deprivation may be required to examine some
withdrawal symptoms.
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Abuse Liability of Electronic Cigarettes
Little is currently known about the abuse liability of EC’s. Abuse liability can be
defined as the ability of a substance to act as a reinforcer or to elicit pleasurable mood
states (Jasinski, Johnson, and Henningfield, 1984). Ability of an EC to alleviate tobacco
withdrawal symptoms would likely contribute to its reinforcing efficacy. That is, if EC’s
were able to effectively alleviate aversive withdrawal symptoms, it could be predicted
that they would have some degree of abuse liability when used in the presence of CC
withdrawal symptoms. As such, the findings discussed in the previous section would
suggest that EC’s might have some abuse liability among CC smokers who are
experiencing withdrawal symptoms.
Another way of assessing reinforcing efficacy is to use a choice procedure
between an EC and another known reinforcer. To date, only one study has used this
method. Vansickel and colleagues (2013) compared EC’s to money, among regular CC
smokers following 12 hours of CC abstinence, and found an average crossover value (the
point that participants would choose money over 10 puffs of EC or CC) of $1.06 for firstgeneration EC’s with 16 mg/ml vs. $1.50 for CC’s. This suggests that EC’s might have
some abuse liability, but relatively less than CC’s. Another method of assessing abuse
liability is to measure drug liking with subjective effects measures (e.g. visual analog
scales or Likert scales). Although ratings of drug liking do not account for a variety of
other factors that might influence abuse liability of a drug (e.g. societal views of using the
drug, known health risks, availability), this is considered an important aspect to the abuse
liability of a drug (discussed further in Jasinski and Henningfield, 1989). Although scant,
there are a few studies that have assessed liking of EC’s in controlled laboratory studies.

9

In two separate studies, increases in measures associated with liking (i.e. ‘pleasant,’
satisfying,’ taste good’) were observed following administration of participants’ own EC
compared to levels prior to EC use (Vansickel and Eissenberg, 2012, Vansickel, Weaver,
and Eissenberg, 2013). In an earlier study by Vansickel and colleagues (2010)
participants rated first generation EC’s with 16 or 18 mg/ml nicotine concentration
significantly lower than CC’s on measures of liking (i.e. ‘satisfying,’ ‘pleasant’),
suggesting a lower abuse liability for EC’s compared to CC’s. In a study comparing first
generation EC’s with 0 or 16 mg/ml nicotine concentrations, EC’s with 16 mg/ml were
rated higher on measures of liking (i.e. ‘pleasant to use’) compared to EC’s with 0 mg/ml
(Bullen et al., 2010), suggesting that presence of nicotine in an EC contributes to their
abuse liability. This is congruent with research demonstrating nicotine dose-dependent
relationships in abuse liability of CC’s (Henningfield, Miyasato, and Jasinski, 1985). In a
study comparing first-generation EC’s with 18 mg/ml nicotine concentrations among
regular EC smokers, participants endorsed “satisfaction” following EC use (Dawkins and
Corcoran, 2014). In a study examining EC use over 72-hours, first-generation EC’s with
11 mg/ml nicotine concentrations were rated less ‘satisfying’ than CC’s (Norton, June,
and O’Connor, 2014). In a study comparing the effects of first- and second-generation
EC’s with 18 mg/ml nicotine concentrations among regular EC users, greater ratings of
‘satisfying’ were reported following second-generation EC’s compared to first-generation
EC’s (Farsalinos et al., 2014). This suggests that the specific type of EC being used
contributes to the abuse liability of EC’s.
Although the aforementioned studies provide some evidence for the abuse
liability of EC’s, there are several limitations that must be acknowledged. It has been
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suggested that in order to effectively assess abuse liability, the drug under consideration
should be administered in at least two different dosages, with placebo and positive
control conditions for comparison (Jasinski and Henningfield, 1989). Although the abuse
liability of an EC may represent factors beyond nicotine (e.g. visual and tactile stimuli
associated with handling and inhaling vapor from these devices), nicotine likely
constitutes a major contributor to the abuse liability of EC’s (evidenced by Bullen et al.,
2010). If this is the case, the fact that none of the aforementioned studies utilized a
meaningful range of nicotine dose concentrations is a limitation on the research of abuse
liability of EC’s thus far. Additionally, some of these studies did not utilize a placebo
condition or some type of positive control condition (i.e. a CC), making quantification of
abuse liability difficult. As such, further research on the effects of multiple doses of
nicotine and their relative effects compared to placebo and control conditions may better
characterize the abuse liability of EC’s.
Public opinion is divided on whether EC’s could serve as a useful smoking
cessation tool for CC smokers, or whether they pose an additional risk to public health.
This reflects the lack of consensus on the health effects (for review see Callahan-Lyon,
2014) and abuse liability (for review see Evans and Hoffman, 2014) of these devices. In
order for current or future users of EC’s and public health officials to make informed
decisions about EC use in the future, further research is required on both these issues. In
order to provide information on the abuse liability and ability of EC’s to alleviate
withdrawal symptoms engendered by CC deprivation in individuals with minimal EC
experience, a research study that examines the physiological, subjective, and cognitive
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effects of multiple nicotine concentrations of EC’s, on CC smokers deprived of tobacco
for 24 hours, was conducted.
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CHAPTER TWO: METHODS
Participants
Eight healthy adults (2 females), between 22 and 47 years of age, were recruited
with online advertisements and flyers placed in the local community. Individuals
responding to advertisements completed a telephone interview or Internet-based
questionnaire comprised of questions about general health status and tobacco and
electronic cigarette use history. Sample size was chosen based on previous abuse liability
studies with similar designs (e.g. Vansickel and Eissenberg, 2012; Henningfield,
Miyasato, and Jasinski, 1985; Babalonis et al., 2013). Individuals who met study criteria
over the phone or Internet were invited into the lab for a screening visit. Screening visits
consisted of a battery of medical and psychological questionnaires including the
Structured Clinical Interview for DSM-IV (SCID), one-year timeline follow-back for CC
use, Fagerstrom test for nicotine dependence, a drug-use history questionnaire, and blood
chemistry, liver function, and urinalysis tests. To be eligible to participate participants
had to report smoking an average of 10 or more tobacco cigarettes per day for at least
one-year, and not report being a regular electronic cigarette user (defined as daily use of
an EC for the past seven-days). Individuals were excluded if they had a history of
significant medical illness (e.g., cardiovascular disease, neurological or psychiatric
disorder), were currently pregnant or breastfeeding, or had any other condition that would
increase risk for study participation. Each participant’s screening information was
examined and approved by a study physician before beginning study procedures. A total
of eight volunteers initiated the study and all eight completed. The University of
Kentucky’s Institutional Review Board approved all study procedures.
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Design
The study consisted of an initial practice day and four two-day blocks each
comprised of two sessions occurring over two consecutive days. All sessions typically
occurred at the same time each day. Baseline sessions were incorporated to capture
measurements of participants following typical tobacco use behaviors, while deprivation
days were used to measure changes from baseline following 24-hour tobacco deprivation,
and relative changes following use of an EC or CC. A placebo-controlled, randomized
within-subjects design was used to examine the behavioral effects of nicotine
concentrations distributed by an EC on deprivation days. Treatment conditions consisted
of smoking a preferred (i.e., own) brand cigarette (not blinded) or puffing from an EC
delivering vapor from liquid with nicotine concentrations of 0, 8, or 16 mg/ml under
double-blind conditions.
Schedule
Practice Day
Previous research has suggested that in order to effectively acquire nicotine from
an EC, naïve users must be sufficiently practiced with use of an EC (Vansickel and
Eiseenberg, 2012). In order to assure sufficient practice with the EC, and familiarity with
study procedures, following 24-hours of tobacco deprivation all study participants
completed a six-session practice day. During each session participants took ten puffs
from an EC delivering vapor from liquid with 16 mg/ml nicotine concentration using a
paced puffing procedure, described below, for a total of 60 puffs over the entire practice
day. There were 30-minutes between each session and assessments measures were
completed before and after each puffing bout to familiarize participants with the
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measures. These data were collected but not analyzed due to possible practice and carryover effects from the last nicotine administration.
Baseline and Deprivation Days
Participants were instructed to abstain from solid food and caffeine four hours
prior to each session. Participants were provided with a standard fat- and caffeine-free
snack shortly after arrival. Sessions lasted approximately one hour. At the start of every
session participants completed field sobriety, breath (Alcohol Sensor III, Intoximeters,
Inc.; piCO Carbon Monoxide Monitor, Bedfont Scientific), and urine tests (cocaine,
benzodiazepine, barbiturate, marijuana, amphetamine, and opiate drug use using OnTrak
TestStik, Varian, Inc.; pregnancy using Clearview HCG II, Unipath, Ltd). During CC
and EC use participants were cued by a laptop computer to take 10 two-second puffs,
with 30-second inter-puff intervals. Both CC’s and EC’s were inhaled through a
mouthpiece connected to a volumetric transducer in order to verify whether the
participant was inhaling in accordance to the puffing procedure. Since the volumetric
transducer was not calibrated for an EC, these data were collected but not analyzed. Use
of the volumetric transducer, however, did not impede or restrict inhalation of the EC or
CC in any way.
Baseline and deprivation days in two-day blocks occurred on consecutive days
with at least 48 hours separating each two-day block. During each session, assessment
measures were completed approximately 20-minutes after arrival (immediately preceding
EC or CC use), and immediately after EC or CC use. On baseline days, following
unrestricted smoking prior to arriving at the lab, a non-blinded CC of the participants
preferred brand was administered using the paced puffing procedure. On deprivation
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days, following 24-hours of tobacco and nicotine deprivation (as verified by CO levels ≤
6 ppm or 10% of their CO level from the previous baseline day [whichever was higher]),
participants completed cognitive tasks and self-report questionnaires before and after
using a single CC of their preferred brand (baseline and deprivation days), or EC
containing liquid with a nicotine concentration of 0, 8, or 16 mg/ml (deprivation days).
Assessments and Tasks
Minnesota Nicotine Withdrawal Scale (MNWS)(Hughes and Hatsukami, 1986;
Hughes and Hatsukami, 2008): Thirteen items from the MNWS were used to examine
effects of tobacco deprivation and alleviation from withdrawal symptoms after CC or EC
use. Two questions associated with sleep (i.e. “insomnia, sleep problems, awakening at
night” and “dreaming or nightmares”) were not used. Participants rated the following
items on an ordinal scale ranging from 0 (“none”) to 4 (“severe”): “angry, irritable,
frustrated,” “anxious or nervous,” depressed mood or sad,” desire or craving to smoke,”
difficulty concentrating,” “increased appetite, hungry or weight gain,” “restless,”
“impatient,” “constipated,” “dizziness,” “coughing,” “nauseous,” and “sore throat.”
Questionnaire Smoking Urges-Brief (QSU-B)(Cox, Tiffany, and Christen, 2001):
This brief 10-item questionnaire assesses desire to smoke and anticipated relief from
negative affect by EC or CC use. Responses are submitted by using a 100-point sliding
scale anchored on the left by “not at all” and on the right by “extremely.” Previous
research has indicated that this scale is sensitive to CC withdrawal effects (West and
Ussher, 2009).
Visual Analog Scale – Smoking Effects (VAS-SE)(Blank, Sams, Weaver, and
Eissenberg, 2008): the VAS-SE is comprised of ten items that have been shown to be
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sensitive to the effects of nicotine. Participants were asked to rate their current feelings
related to each item by placing a mark on a 100-unit line with the left endpoint of this
continuum labeled “Not at all” and the right endpoint labeled “Extremely.” Items on the
VAS-SE included the following: “confused,” “dizzy,” “headache,” “heart pounding,”
“light-headed,” “nausea,” “nervous,” “salivation,” “sweaty,” and “weak.”
Visual Analog Scale – Post Smoking (VAS-PS): Six items were used to assess the
effects of using an EC or CC. Participants were asked to rate their current feelings
related to each item by placing a mark on a 100-unit line with the left endpoint of this
continuum labeled “Not at all” and the right endpoint labeled “Extremely.” Items on the
VAS-PS included the following: “stimulated,” “like the effects,” “want to smoke again,”
“enjoy the e-cigarette,” “crave the e-cigarette,” and “get pleasure from the e-cigarette?”
Digit-Symbol Substitution Task (DSST): Participants completed a two-minute
computerized version of the DSST (McLeod, Griffiths, Bigelow, and Yingling, 1982). In
this revised task a digit-symbol code, consisting of geometric patterns associated with
numbers 1-9, is constantly displayed at the top of the screen. The geometric patterns are
comprised of 9 white and black boxes in 3x3 rows and columns that correspond to
buttons on a 9-key keypad. In the center of the screen a random test digit 1-9 is
displayed. Participants are asked to replicate the geometric pattern at the top of the
screen associated with the test digit by pressing keys in a top-to-bottom order on a 9-key
keypad. The test digit changes after the participant has pressed at least one key for each
of the three rows. Participants are given visual feedback after each key press to indicate
whether they pressed the correct or incorrect key. The DSST has been shown to be
sensitive to nicotine deprivation (Pickworth et al., 1996). Two outcome measures from
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this task were examined, total number of trials completed and percentage of trials
completed that were correct.
Rapid Information Processing Task (RIP)(Fillmore, Marczinski, and Bowman,
2005): Participants completed a 5-min computerized version of the rapid informationprocessing task. During this task single digits were presented on-screen at a rate of 90
digits/min. Participants were instructed to press a key whenever three consecutive odd or
even digits were presented. Initially, each digit was displayed on-screen for 67 ms with
an ISI of 600 ms. Based on performance, the presentation rate increased (after correct
responses) or decreased (after incorrect responses). Previous research has shown that
RIP performance is sensitive to CC nicotine yield in regular tobacco smokers who have
undergone smoking deprivation (Wesnes and Warburton, 1984). Four outcome measures
from this task were examined: average digit rate, reaction time to correctly identified
sequences (hits), percentage of sequences correctly identified (proportion correct), and
number of responses when a sequence was not present (commission errors).
Cardiovascular Measures: Heart rate and blood pressure were recorded using an
automated blood pressure monitor (Dinamap Pro 200, General Electric) before and after
each EC or CC use. Measurements were taken while the participant was seated and took
approximately 60-seconds. Diastolic and systolic blood pressure were consolidated into
estimated mean arterial pressure (MAP) by using the following equation:
𝑀𝐴𝑃 =   

𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 + 2  (𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐)
3
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Drug
The Blu® (Lorillard Technologies, Inc; Greensboro, NC) rechargeable EC was
used for this study. This EC was chosen as a representative of first generation EC’s
because of its wide availability throughout the United States. The white and tan colored
Blu® EC with “Classic Tobacco” liquid flavoring was used to best approximate a CC.
Liquid tanks offered by the manufacturer with varying nicotine concentration (i.e. “none”
0 mg/ml, “low” 6-8 mg/ml, and “high” 14-16 mg/ml) were used to experimentally
manipulate nicotine concentrations. Each disposable liquid tank was used for a
maximum of four 10-puff sessions. Participants’ preferred brand of CC was supplied for
own brand (OB) conditions. Adherence to the paced puffing procedure was verified via
video cameras and a volumetric transducer that tracked puffing behavior.
Data Analysis
To examine smoking on baseline days separate mixed models were fit for all
variables, except VAS-PS variables, with session (pre-smoking on baseline days and
post-smoking on baseline days) as the independent variable. To examine tobacco
deprivation effects, two separate analyses were conducted. To examine the difference
between unrestricted smoking and 24-hour tobacco deprivation separate mixed models
were fit for all variables, except VAS-PS variables, with session (analysis 1: pre-smoking
on baseline days and prior to EC or CC use on deprivation days; analysis 2: post-smoking
on baseline days and prior to EC or CC use on deprivation days) as an independent
variable. Differences between the aforementioned time points were evaluated for
statistical significance by using t-tests to compare the least squares means derived by
each mixed model. To examine acute EC or CC effects according to condition, a mixed
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model was fit on withdrawal and acute effects measures with ratings following EC or CC
use on deprivation days as the dependent variable, condition (own brand cigarette or EC
with 0, 8 or 16 mg/ml of nicotine) as an independent variable, and ratings prior to EC or
CC use on deprivation days as a covariate. When significant effects of condition were
indicated, post-hoc pairwise comparisons of least-square means of each condition were
conducted. To determine whether there were significant changes on withdrawal
associated measures (i.e. RIP, DSST, MNWS, QSU-B, and HR and blood pressure) based
on condition, a mixed model was fit on the difference between measures preceding and
following EC or CC use on deprivation days with dose as the independent variable.
When a significant effect of dose was indicated in these models t-tests were conducted
for each condition to determine whether the difference between measures preceding or
following EC or CC use was significantly different from 0. Hochberg’s step-up
procedure (Hochberg, 1988) was used to control error rates for each family of pairwise
comparisons. Mixed models were fit using PROC MIXED in the SAS statistical software
package, version 9.3 (SAS Institute Inc., Cary, NC). The alpha level for all analyses was
set at 0.05.
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CHAPTER THREE: RESULTS
Demographic and Clinical Variables:
Demographic and clinical variables are summarized in Table 3a. Participants
were primarily Caucasian (87.5%) and male (75%), smoked an average of 19.7 ± 9.4
cigarettes per day, and had an average score of 5.6 on the FTND. Minimal alcohol use
was reported, with all participants reporting some use at an average frequency of less
than one day per week. Participants reported minimal marijuana use, with five non-users
and three users reporting an average of 2.3 occasions per month.
Carbon monoxide levels decreased from an average of 29.0 ppm (SD=18.3) prior
to smoking on baseline days, to an average of 5.5 ppm (SD=1.6) following 24 hours of
tobacco deprivation. Average pre- and post-deprivation carbon monoxide levels for each
participant are displayed in Table 3d.
Effects of OB smoking on baseline days (under column ‘baseline smoking’), 24hour tobacco deprivation (under column ‘24-Dep’), and measures following OB or EC
use relative to measures prior to use (following 24-hr deprivation), are summarized in
Table 3b. Direct comparisons between OB and EC use conditions are summarized in
Table 3c.
RIP:
Baseline Smoking and Deprivation Effects: There were no significant changes in
digit presentation rate, reaction time on correct trials, proportion correct, or commission
errors after smoking OB on baseline days. Digit rate on the RIP significantly increased
[t(7)=4.76, p=.002] from 90.7 digits per minute after smoking on baseline days to 98.8
digits per minute after 24-hours of tobacco deprivation; this rate was not significantly
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different from pre-smoking rate on baseline days (Figure 3a). Reaction time on correct
trials significantly decreased [i.e., improved, t(7)=3.49, p=.01] after tobacco deprivation
from 346.5 ms after smoking on baseline days to 323.2 ms after 24-hours of tobacco
deprivation; this time was not significantly different from the pre-smoking reaction time
on baseline days. Proportion correct on the RIP significantly increased [t(7)=4.15,
p=.004] from 55.8% correct after smoking on baseline days to 61.6% correct after 24hours of tobacco deprivation; this rate was not significantly different from pre-smoking
rate on baseline days.
Post-Deprivation OB or EC Effects: There were no significant changes in RIP
task performance after OB or EC conditions.
DSST:
Baseline Smoking and Deprivation Effects: On baseline days, total trials
completed during the two-minute DSST significantly increased [t(7)=2.37, p=.05] from
56.2 trials to 58.6 trials after smoking OB. After 24-hours of tobacco deprivation total
trials completed significantly decreased [t(7)=3.22, p=.01] from 58.6 to 54.9 trials
(Figure 3b), though 54.9 trials was not significantly different from trials completed presmoking on baseline days.
Post-Deprivation OB or EC Effects: A main effect of condition was observed on
total trials completed [F(3, 21)=3.18, p=.05], with significantly more trials completed
following using OB [t(21)=2.85, p=.01] and EC with nicotine levels of 8 mg/ml
[t(21)=3.11, p=.005] compared to pre-smoking on deprivation days (Figure 3b). Based
on the data presented in Figure 3b, which was counterintuitive to the statistical finding of
significantly more trials completed following 8 mg/ml, a follow-up analysis of
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performance measures prior to OB or EC use on deprivation days was conducted. This
revealed a main effect of condition prior to OB or EC use [F(3, 21)=7.56, p=.001], with
significantly fewer trials completed prior to 8 mg/ml compared to the 0 and 16 mg/ml
conditions.
VAS-Smoking Effects:
Baseline Smoking and Deprivation Effects: On baseline days, ratings of ‘dizzy’
on the 100-point VAS scale significantly increased [t(7)=2.41, p=.05] from 0.3 to 4.0
after smoking OB. Ratings of ‘heart pounding’ significantly increased [t(7)=3.05, p=.02]
from 0.3 to 4.3 after smoking OB and significantly decreased [t(7)=2.93, p=.01] from 4.3
to 0.5 following 24-hours of tobacco deprivation, though 0.5 was not significantly
different from pre-smoking ratings on baseline days. On baseline days, ratings of
‘lightheaded’ significantly increased [t(7)=3.62, p=.009] from 0.2 to 6.0 after smoking
OB and significantly decreased [t(7)=3.59, p=.009] from 6.0 to 0.2 after 24-hours of
tobacco deprivation; 0.2 was not significantly different from pre-smoking ratings on
baseline days.
Post-Deprivation OB or EC Effects: On deprivation days, a main effect of
condition was observed on change in feeling ‘lightheaded’ after OB or EC use [F(3,
21)=8.90, p<.001], with significantly higher ratings following smoking OB [t(21)=4.31,
p<.001] compared to pre-smoking. A relative difference between conditions was
indicated on feeling ‘lightheaded’ [F(3, 20)=7.49, p<.002], with significantly higher
ratings of feeling ‘lightheaded’ following OB (19.1) compared to EC nicotine levels of 0
(0.8), 8 (2.8), or 16 mg/ml (0.9).
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MNWS:
Baseline Smoking and Deprivation Effects: On baseline days, ratings of ‘desire or
craving to smoke’ on the five-point MNWS significantly decreased [t(7)=6.94, p<.001]
from 1.8 to 0.5, ratings of ‘dizziness’ significantly increased [t(7)=2.85, p=.03] from 0 to
0.3 and ratings of ‘sore throat’ significantly increased [t(7)=3.12, p=.02] from 0 to 0.2
after smoking OB. Ratings on eight of the 13 MNWS items (i.e. feeling ‘angry, irritable,
or frustrated,’ ‘depressed mood or sad,’ ‘desire or craving to smoke,’ ‘difficulty
concentrating,’ ‘increased appetite, hungry, or weight gain,’ ‘restless,’ ‘impatient’)
significantly increased from post-smoking on baseline days to after tobacco deprivation,
with levels all exceeding those reported pre-smoking on baseline days. Ratings on three
of the 14 MNWS items (i.e. feeling ‘dizziness,’ ‘coughing,’ ‘sore throat’) significantly
decreased after tobacco deprivation, although they did not decrease below levels reported
pre-smoking on baseline days. Total Scores on the MNWS ranged from 0-52 and
significantly increased [t(7)=5.48, p<.001] from 2.3 to 7.2 after 24-hours of tobacco
deprivation, which exceeded levels reported pre-smoking on baseline days.
Post-Deprivation OB or EC Effects: On deprivation days, a main effect of
condition was observed on change in rating of ‘desire or craving to smoke’ [F(3,
21)=3.29, p=.04], with significantly lower ratings following smoking OB [t(21)=5.34,
p<.001] compared to pre-smoking ratings. A relative difference between conditions was
indicated on feeling ‘desire or craving to smoke’ [F(3, 20)=5.17, p=.008], with
significantly lower ratings following OB (0.6) compared to EC nicotine levels of 0 (2.5),
8 (1.9), or 16 mg/ml (2.0). A main effect of condition was indicated on ‘coughing’ [F(3,
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20)=3.11, p=.05], but there were no significant differences between conditions after
correcting for multiple comparisons.
QSU-B:
Baseline Smoking and Deprivation Effects: On baseline days, ratings on nine of
10 items of the 100-point QSU-B scale decreased after smoking OB. The largest
decreases were observed on ‘if it were possible I would probably smoke now,’ which
decreased from 49.8 to 8.0 following smoking OB, and ‘’I am going to smoke as soon as
possible,’ which decreased from 44.9 to 8.6 following smoking OB. After 24-hours of
tobacco deprivation, ratings on all variables of the QSU-B significantly increased. All of
these increases, except those reported for ‘smoking would make me less depressed,’
significantly exceeded ratings reported prior to smoking on baseline days. The largest
increases were observed on ‘if it were possible I would probably smoke now,’ which
increased from 8.0 to 75.2 following 24-hours of tobacco deprivation, and ‘I am going to
smoke as soon as possible,’ which increased from 8.6 to 69.8 following 24-hours of
tobacco deprivation.
Post-Deprivation OB or EC Effects: A main effect of condition was observed on
change in rating of ‘I have a desire for a cigarette right now’ [F(3, 21)=7.44, p=.001],
with significantly lower ratings following smoking OB [t(21)=6.51, p<.001] compared to
pre-smoking on deprivation days. Comparable main effects of condition were observed
on all other QSU-B variables except ‘nothing would be better than a cigarette right now,’
‘I could control things better right now if I could smoke,’ ‘I would do almost anything for
a cigarette now,’ and ‘smoking would make me less depressed,’ which did not show
significant changes following OB or EC use compared to levels prior to OB or EC use on
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deprivation days. Between conditions, on ‘I have a desire for a cigarette right now’ there
were significantly lower ratings following OB (18.4) compared to EC nicotine levels of 0
(58.4), 8 (50.4), or 16 mg/ml (56.4) (Figure 3f). Although following OB or EC use, no
condition was significantly lower than levels prior to OB or EC use on deprivation days,
between conditions, on ‘nothing would be better than smoking a cigarette right now’
there were significantly lower ratings following OB (12.5) compared to EC with 0 (40.5),
8 (36.8), or 16 mg/ml (39.9). Between conditions, on ‘if it were possible I would
probably smoke now’ there were significantly lower ratings following OB (13.8)
compared to EC nicotine levels of 0 (65.8), 8 (55.1), or 16 mg/ml (57.3). Between
conditions, on ‘all I want right now is a cigarette’ there were significantly lower ratings
following OB (15.9) compared to EC with nicotine levels of 0 (46.5) or 16 mg/ml
(40.75). Between conditions, on ‘I have an urge for a cigarette’ there were significantly
lower ratings following OB (13.5) compared to EC with 0 (59.4), 8 (50.5), or 16 mg/ml
(46.1). Between conditions, on ‘a cigarette would taste good right now’ after OB or EC
use [F(3, 21)=4.87, p=.01] there were significantly lower ratings following smoking OB
[t(21)=5.77, p<.001] compared to pre-smoking on deprivation days. Between conditions,
on ‘a cigarette would taste good now’ there were significantly lower ratings following
OB (17.1) compared to EC with nicotine levels of 0 (55.5), 8 (46.1), or 16 mg/ml (51.0).
Between conditions, on ‘I am going to smoke as soon as possible’ there were
significantly lower ratings following smoking OB [t(21)=5.00, p<.001] compared to presmoking on deprivation days. Between conditions, on ‘I am going to smoke as soon as
possible’ [F(3, 20)=8.82, p=.006] there were significantly lower ratings following OB
(18.5) compared to EC with nicotine levels of 0 (64.6), 8 (52.5), or 16 mg/ml (57.5).
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HR and MAP:
Baseline Smoking and Deprivation Effects: No significant changes in heart rate or
mean arterial pressure were observed post OB smoking on baseline days. Heart rate
significantly decreased [t(7)=7.51, p<.001] from 84.0 bpm to 72.5 bpm after 24-hours of
tobacco deprivation, which was significantly lower [t(7)=5.18, p=.001] than pre-smoking
on baseline days. Mean arterial pressure significantly decreased [t(7)=4.35, p=.003] from
102.6 to 96.0 after 24-hours of tobacco deprivation, though this level was not
significantly lower than pre-smoking levels on baseline days.
Post-Deprivation OB or EC Effects: A main effect of condition was observed on
heart rate [F(3, 21)=3.45, p=.04], with significantly higher heart rate following OB
[t(21)=4.95, p<.001] compared to pre-smoking on deprivation days. A relative difference
between conditions was indicated on heart rate [F(3, 20)=8.82, p=.006], with
significantly greater heart rate following OB (90.1) compared to EC with nicotine levels
of 16 mg/ml (75.0).
VAS-Post Smoking:
Post-Deprivation OB or EC Effects: A significant effect of condition was detected
on ratings of ‘stimulated’ (Figure 3e) [F(3, 21)=4.52, p=.01] and ‘enjoy the e-cigarette’
[F(3, 21)=4.34, p=.02], with significantly higher ratings following OB compared to EC
with 0 mg/ml. Significant effects of condition were also detected on ratings of ‘like
effects’ [F(3, 21)=5.23, p=.007] and ‘want to smoke again’ [F(3, 21)=11.82, p<.001],
with significantly higher ratings following OB (68.2) compared to EC with nicotine
levels of 0 (26.8), 8 (29.4), or 16 mg/ml (38.4) (Figure 3d). A significant effect of
condition was detected on ratings of ‘get pleasure from the e-cigarette’ [F(3, 21)=4.34,
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p=.02], but there were no significant differences between conditions after correcting for
multiple comparisons.
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Table 3a. Demographic and Clinical Variables
Total N = 8
Gender
Female, N (%)
Age, years (mean, SD)
Education, years (mean, SD)
Race
Caucasian, N (%)
Other, N (%)
Fagerstrom Test for Nicotine Dependence Score,
(mean, SD)
Tobacco, cigarettes per day (mean, SD)
Caffeine, days/week (mean, SD)
Alcohol, days/week (mean, SD)
Marijuana, occasions/month (mean, SD)
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2 (25.0)
34 ± 9.1
14.4 ± 2.1
7 (87.5)
1 (12.5)
5.6 ± 2.1
19.7 ± 9.4
5.7 ± 2.6
.82 ± .81
.88 ± 1.6

Table 3b. Cognitive, subjective, and physiological effects by session and condition

Variable
Rapid Information Processing Task
Digit rate
Reaction time on correct trials
Proportion correct
Commission errors
Digit Symbol Substitution Task
Total trials completed
Percentage trials correct
Visual Analog Scale – Smoking effects
Confused
Dizzy
Headache
Heart pounding
Lightheaded
Nausea
Nervous
Salivation
Sweaty
Weak
Minnesota Nicotine Withdrawal Scale
Angry, irritable, or frustrated
Anxious or nervous
Depressed mood or sad
Desire or craving to smoke
Difficulty concentrating
Increased appetite, hungry, or weight gain
Restless
Impatient
Constipated
Dizziness
Coughing
Nauseous
Sore throat
Total Score

Baseline
Smoking

24-Dep

Baseline
vs.
24-Dep	
  

Own
Brand

Electronic Cigarette Nicotine
Concentrations
0 mg/ml
8 mg/ml
16 mg/ml

!**

!**
"*
!**

!*

"*

!**

!*

"

!**

"*
"**

!***

!*
!*
!**

"***

!***

!***	
  

!*
!***
!**
!*
!*
!**

!*	
  
!***
!**	
  
!*	
  
!*	
  
!**	
  

!*

"*
"*

!*

"*
!***

!***
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"***

Table 3b (continued).
Nothing would be better than smoking a cigarette
right now
If it were possible I would probably smoke now
I could control things better right now if I could
smoke
All I want right now is a cigarette
I have an urge for a cigarette
A cigarette would taste good now
I would do almost anything for a cigarette now
Smoking would make me less depressed
I am going to smoke as soon as possible
Heart Rate and Blood Pressure
Heart rate
Mean arterial pressure

"***

!***

!**	
  

"***
"**

!***
!**

!***
!*	
  

"***

"***
"***
"***
"**

!***
!***
!***
!***
!*
!***

!**
!***
!***
!**	
  

"***
"***
"***

!**	
  

"***

"***
"**

"**

!***

"***

Baseline smoking = results of comparisons between pre- and post-smoking on baseline days. 24-Dep = results of comparisons between post-smoking on baseline
days and prior to OB or EC use on deprivation days. Baseline vs. 24-Dep = results of comparisons between pre-smoking on baseline days and prior to OB or EC
use on deprivation days. Own brand and electronic cigarette nicotine concentration columns represent comparisons between condition and prior to OB or EC use
on deprivation days. *p≤.05, **p≤.01, ***p≤.001
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Table 3c. Cognitive, subjective, and physiological effects of using electronic
cigarettes compared to own brand cigarettes
Electronic	
  Cigarette	
  Nicotine	
  
Concentrations#	
  
Variable	
  
Rapid	
  Information	
  Processing	
  Task	
  
	
  	
  	
  	
  	
  	
  	
  Digit	
  rate	
  
	
  	
  	
  	
  	
  	
  	
  Reaction	
  time	
  on	
  correct	
  trials	
  
	
  	
  	
  	
  	
  	
  	
  Proportion	
  correct	
  
	
  	
  	
  	
  	
  	
  	
  Commission	
  errors	
  
Digit	
  Symbol	
  Substitution	
  Task	
  
	
  	
  	
  	
  	
  	
  	
  Total	
  trials	
  completed	
  
	
  	
  	
  	
  	
  	
  	
  Percentage	
  trials	
  correct	
  
Visual	
  Analog	
  Scale	
  –	
  Smoking	
  effects	
  
	
  	
  	
  	
  	
  	
  	
  Confused	
  
	
  	
  	
  	
  	
  	
  	
  Dizzy	
  
	
  	
  	
  	
  	
  	
  	
  Headache	
  
	
  	
  	
  	
  	
  	
  	
  Heart	
  pounding	
  
	
  	
  	
  	
  	
  	
  	
  Lightheaded	
  
	
  	
  	
  	
  	
  	
  	
  Nausea	
  
	
  	
  	
  	
  	
  	
  	
  Nervous	
  
	
  	
  	
  	
  	
  	
  	
  Salivation	
  
	
  	
  	
  	
  	
  	
  	
  Sweaty	
  
	
  	
  	
  	
  	
  	
  	
  Weak	
  
Visual	
  Analog	
  Scale	
  –	
  Post	
  Smoking	
  
	
  	
  	
  	
  	
  	
  	
  Stimulated	
  
	
  	
  	
  	
  	
  	
  	
  Like	
  effects	
  
	
  	
  	
  	
  	
  	
  	
  Want	
  to	
  smoke	
  again	
  
	
  	
  	
  	
  	
  	
  	
  Enjoy	
  the	
  e-‐cigarette	
  
	
  	
  	
  	
  	
  	
  	
  Crave	
  the	
  e-‐cigarette	
  
	
  	
  	
  	
  	
  	
  	
  Get	
  pleasure	
  from	
  the	
  e-‐cigarette	
  
Minnesota	
  Nicotine	
  Withdrawal	
  Scale	
  
	
  	
  	
  	
  	
  	
  	
  Angry,	
  irritable,	
  or	
  frustrated	
  
	
  	
  	
  	
  	
  	
  	
  Anxious	
  or	
  nervous	
  
	
  	
  	
  	
  	
  	
  	
  Depressed	
  mood	
  or	
  sad	
  
	
  	
  Desire	
  or	
  craving	
  to	
  smoke	
  
	
  	
  	
  	
  	
  	
  	
  Difficulty	
  concentrating	
  
	
  	
  	
  	
  	
  	
  	
  Increased	
  appetite,	
  hungry,	
  or	
  weight	
  gain	
  
	
  	
  	
  	
  	
  	
  	
  Restless	
  
	
  	
  	
  	
  	
  	
  	
  Impatient	
  
	
  	
  	
  	
  	
  	
  	
  Constipated	
  
	
  	
  	
  	
  	
  	
  	
  Dizziness	
  
	
  	
  	
  	
  	
  	
  	
  Coughing	
  
	
  	
  	
  	
  	
  	
  	
  Nauseous	
  
	
  	
  	
  	
  	
  	
  	
  Sore	
  throat	
  
	
  	
  	
  	
  	
  	
  	
  Total	
  Score	
  
Questionnaire	
  of	
  Smoking	
  Urges	
  –	
  Brief	
  
	
  	
  	
  	
  	
  	
  	
  I	
  have	
  a	
  desire	
  for	
  a	
  cigarette	
  right	
  now	
  
	
  	
  	
  	
  	
  	
  	
  Nothing	
  would	
  be	
  better	
  than	
  smoking	
  a	
  cigarette	
  right	
  now	
  
	
  	
  	
  	
  	
  	
  	
  If	
  it	
  were	
  possible	
  I	
  would	
  probably	
  smoke	
  now	
  
	
  	
  	
  	
  	
  	
  	
  I	
  could	
  control	
  things	
  better	
  right	
  now	
  if	
  I	
  could	
  smoke	
  
	
  	
  	
  	
  	
  	
  	
  All	
  I	
  want	
  right	
  now	
  is	
  a	
  cigarette	
  
	
  	
  	
  	
  	
  	
  	
  I	
  have	
  an	
  urge	
  for	
  a	
  cigarette	
  
	
  	
  	
  	
  	
  	
  	
  A	
  cigarette	
  would	
  taste	
  good	
  now	
  
	
  	
  	
  	
  	
  	
  	
  I	
  would	
  do	
  almost	
  anything	
  for	
  a	
  cigarette	
  now	
  
	
  	
  	
  	
  	
  	
  	
  Smoking	
  would	
  make	
  me	
  less	
  depressed	
  
	
  	
  	
  	
  	
  	
  	
  I	
  am	
  going	
  to	
  smoke	
  as	
  soon	
  as	
  possible	
  
Heart	
  Rate	
  and	
  Blood	
  Pressure	
  
	
  	
  	
  	
  	
  	
  	
  Heart	
  rate	
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Table 3c. (continued)
#: Comparison with Own Brand smoking condition. Arrows represent values following EC use that were
significantly above (") or below (!) values for own brand cigarettes following EC use on deprivation days;
*p≤.05, **p≤.01, ***p≤.001
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Table 3d. Carbon monoxide levels for each participant
Participant #
1
2
3
4
5
6
7
8
Total average

Pre-smoking
Baseline Days
25.3
26.0
41.3
61.3
23.0
35.5
11.5
9.8
29.0 ± 18.3

Pre-smoking
Deprivation Days
3.5
4.3
7.3
5.5
5.5
6.5
5.3
6.0
5.5 ± 1.6
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Figure 3a: Rapid Information Processing Task: Digit Rate

Average number of digits presented per minute on the Rapid Information Processing Task. After 24-hours of tobacco deprivation trial
rate significantly increased [t(7) = 4.76, p =.002]. There were no statistically significant differences in trial rate following OB or EC
use on baseline or deprivation days.
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Figure 3b: Digit Symbol Substitution Task: Total Trials Completed Per Session

Number of trials completed on the two-minute Digit Symbol Substitution Task. A significant increase in total trials completed was
observed following baseline smoking [t(7) = 2.37, p =.05] and a significant decrease was observed following 24-hour tobacco
deprivation [t(7) = 3.22, p =.01]. Compared to levels prior to OB or EC use on deprivation days, there were significant increases in
total trials completed following using electronic cigarettes dispensing vapor from the 8 mg/ml nicotine concentration [t(21) = 3.11, p
=.005] or OB [t(21) = 2.85, p =.01].
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Figure 3c: Self-report of “like effects”

Self-report of “like effects” on a 100-point visual analog scale. Following OB or EC use after 24-hours of tobacco deprivation, own
brand cigarettes engendered significantly greater reports of ‘like effects’ compared to electronic cigarettes with 0 [t(21) = 3.56, p
=.002], 8 [t(21) = 3.10, p =.005], or 16 mg/ml [t(21) = 2.89, p <.009].
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Figure 3d: Self-report of “want to smoke again?”

Subjective ratings of “want to smoke again?” on a 100-point visual analog scale. Following OB or EC use after 24-hours of tobacco
deprivation, own brand cigarettes engendered significantly lower reports of ‘want to smoke again’ compared to electronic cigarettes
with 0 [t(21) = 5.55, p <.001], 8 [t(12) = 4.19, p <.001], or 16 mg/ml [t(12) = 4.39, p <.001].
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Figure 3e: Self-report of feeling “stimulated”

Subjective ratings of feeling “stimulated” on a 100-point visual analog scale. Following OB or EC use after 24-hours of tobacco
deprivation, own brand cigarettes engendered significantly greater reports of ‘stimulated’ compared to electronic cigarettes dispensing
0 mg/ml nicotine [t(21) = 3.50, p =.002].
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Figure 3f: Self report of “I have a desire for a cigarette right now”

Subjective ratings of “I have a desire for a cigarette right now” on a 100-point visual analog scale. A significant decrease was
observed following baseline smoking [t(7) = 7.45, p <.001] and a significant increased was observed following 24-hour tobacco
deprivation [t(7) = 10.81, p <.001]. Levels prior to OB or EC use on deprivation days were significantly higher than pre-smoking
levels on baseline days [t(7) = 5.71, p <.001]. Following OB or EC use on deprivation days, own brand cigarettes engendered
significantly lower ratings compared to electronic cigarettes dispensing vapor from 0 [t(20) = 5.83, p <.001], 8 [t(20) = 4.73, p <.001],
or 16 mg/ml [t(20) = 5.40, p <.001] nicotine concentrations.
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CHAPTER FOUR: DISCUSSION
Overall Conclusions
This study compared cognitive, self-reported, and physiological effects of a
commercially available first-generation EC, with experimentally manipulated nicotine
concentrations, to preferred brand CC’s in a sample of regular tobacco smokers,
following 24-hours of tobacco deprivation. Tobacco deprivation engendered typical

se

self-report (MNWS and QSU-B) and physiological (heart rate) withdrawal symptoms.
Smoking CC’s after 24-hours of tobacco deprivation ameliorated many of the self-report
(e.g. six of 10 QSU-B items) and physiological effects (heart rate) associated with
tobacco deprivation. On all these measures of tobacco withdrawal, no attenuation of
withdrawal effects from EC use was indicated. On key abuse liability measures (e.g.,
liking), there were no significant changes from ratings prior to EC use following EC use
(regardless of nicotine concentration), while OB smoking engendered significant
changes on these ratings.
Tobacco Withdrawal Symptoms
In order to assess tobacco withdrawal effects, participants were required to
abstain from tobacco use for 24-hours prior to assessment of OB or EC use. Baseline
data were collected prior to tobacco deprivation in order to determine relative changes
following typical smoking behaviors (unrestricted smoking) compared to smoking after
24-hour tobacco abstinence. Self-reported symptoms of withdrawal (MNWS and QSUB), exhaled CO levels, and heart rate all showed significant changes following 24-hour
tobacco deprivation, which were commensurate with previous research on the effects of
tobacco deprivation (e.g. Hughes and Hatsukami, 1986; Bell et al., 1999; Lee et al.,
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2011). This verifies that the 24-hour deprivation period used in this study was effective
at inducing tobacco withdrawal.
Withdrawal effects were defined as measures that significantly changed from
levels following smoking on baseline days to levels significantly different from presmoking levels on baseline days after 24-hours of tobacco deprivation (e.g. heart rate).
Acute effects were defined as measures that showed changes from pre- to post-smoking
on baseline days and no significant deviation from pre-smoking levels on baseline days
following 24-hours of tobacco deprivation. For example, lightheadedness increased from
pre- to post-smoking levels on baseline days, while returning to levels not significantly
different from pre-smoking levels on baseline days following 24-hours of tobacco
deprivation. Similarly, total trials completed on the DSST increased following smoking
on baseline days, while returning to levels that were not significantly different than presmoking levels on baseline days following 24-hours of smoking deprivations. On
measures that followed this pattern, pre-smoking measurements on baseline days were
compared to measurements after 24-hours of tobacco deprivation in order to determine if
a withdrawal effect was present. In accordance with this criteria, dizziness (on the VASSE and MNWS), heart pounding, feeling lightheaded, sore throat, total trials completed
on the DSST, and performance on the RIP were considered acute effects.
Following 24-hour tobacco deprivation digit rate increased on the RIP, which was
likely driven by an increase in proportion correct (because commission errors did not
significantly change following 24-hour tobacco deprivation), while reaction time on
correct trials on the RIP decreased. There were no acute smoking effects on baseline
days, which could suggest that changes in performance following 24-hour tobacco
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deprivation on the RIP were due to tobacco withdrawal and not an acute effect. Yet,
since performance on the RIP prior to OB or EC use on deprivation days did not
significantly differ from performance prior to smoking on baseline days, it could not be
concluded that changes in RIP performance were due to tobacco deprivation. There were
also no significant changes in RIP performance following any the OB or EC conditions.
This is incongruent with previous research reports showing changes in RIP performance
following tobacco deprivation, and acute smoking of CC’s (e.g. Wesnes and Warburton,
1984). This might be due to the large variance in performance on this task not
attributable to OB or EC condition (evident in Figure 3a). Additionally, practice effects
from multiple administrations of this task (before and after OB or EC use on baseline and
deprivation days) may have confounded these results, such that clear effects of OB or EC
use were not observable. Since the primary purpose of this study was to examine
management of withdrawal symptoms by EC’s compared to CC’s, we cannot make any
conclusions about the ability of EC’s to manage cognitive withdrawal symptoms on this
task due to a lack of a positive control.
Number of trials completed on the DSST significantly decreased following 24hour tobacco deprivation but not relative to pre-smoking on baseline days. This suggests
an acute smoking effect, which was replicated on deprivation days following smoking
OB. Although there was a significant increase in total trials completed following 8
mg/ml EC’s, Figure 3b demonstrates that performance following 8 mg/ml on deprivation
days was actually decreased compared to other conditions. A follow-up analysis of
performance on deprivation days, prior using OB or EC, indicated that total trials
completed on days prior to using an EC with 8 mg/ml was significantly lower than
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compared to total trials completed preceding all other conditions. Thus, this finding is
likely a spurious result due to significantly lower performance on this measure prior to
using an EC with 8 mg/ml days, and the lack of significant effects following 8 mg/ml on
other measures employed in this study. These results suggest that smoking OB may
enhance cognitive performance on the DSST regardless of deprivation, while using an
EC does not. It has been suggested that changes in cognitive performance measured by
laboratory tasks represents, in part, motivation for smoking, whereby use of tobacco
could serve to enhance cognition (e.g., Evans and Drobes, 2009). Performance on total
trials completed on the DSST in the current study support this notion. Since an acute
effect of smoking OB was shown on the DSST, this might inform abuse liability rather
than withdrawal management. Thus, these results would suggest that EC’s have a lower
abuse liability compared to CC’s with regards to their effects on DSST performance.
Self-reported withdrawal effects were clearly indicated on several measures (i.e.
seven items and total score on the MNWS, all QSU-B items). This is consistent with
previous research using these measures in populations of regular tobacco users who have
undergone a period of tobacco deprivation (Teneggi et al., 2002; West and Ussher, 2009;
Lee et al., 2011). Following smoking OB, self-reported withdrawal symptoms on the
QSU-B significantly decreased on baseline days (nine of 10 QSU-B items) and
deprivation days (10 of 10 QSU-B items). Reports of ‘desire or craving to smoke’ on the
MNWS and six QSU-B items measured on deprivation days significantly decreased
following smoking OB and not using EC’s, suggesting that EC’s are less effective than
OB at managing self-reported withdrawal symptoms. This evidence is consistent with
previous studies that compared EC’s to a CC in tobacco deprived regular CC smokers
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and found that EC’s were less effective than CC’s at reducing tobacco withdrawal
symptoms (Vansickel et al., 2010; Bullen et al., 2010; Norton, June, and O’Connor,
2014). Results of the current study, however, also found that EC’s were unable to
attenuate desires or cravings compared to pre-smoking levels, which is contrary to other
studies that have shown some ability of EC’s to attenuate cigarette cravings in regular CC
smokers (Vansickel et al., 2010; Bullen et al., 2010; Vansickel, Weaver, and Eissenberg,
2012; Dawkins, Turner, and Crowe, 2013). There are multiple possible explanations for
this. Relative to other studies, the current study used a longer period of tobacco
deprivation, which may have yielded greater withdrawal effects that were more difficult
to ameliorate with an EC. There is also a possibility that the specific device used in the
current study might have been less effective at reducing cigarette cravings. For example,
it has been demonstrated that EC’s release differing amounts of nicotine into vapor,
regardless of the concentration of nicotine in their liquid (Goniewicz, Hajek, McRobbie,
2014). Thus, it could be that the EC used in this study was not as capable at delivering
nicotine to the user as were devices used in other studies.
Electronic Cigarettes and Abuse Liability
Measures of liking (i.e. VAS-PS) were sensitive to smoking OB on baseline and
deprivation days. Participants rated OB significantly higher on ‘like effects’ compared to
all nicotine concentrations of EC (Figure 3c), suggesting greater abuse liability for CC’s
compared to the EC conditions tested in this study. This is congruent with the only other
studies that have compared EC’s to CC’s on some measure of liking (Vansickel et al.,
2010; Norton, June, and O’Connor, 2014). Although to a lesser extent than CC’s,
participants did endorse some liking for the EC (average of 31.5 across all EC nicotine
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concentrations), which was independent of nicotine concentrations. This suggests that
EC’s have some abuse liability independent of nicotine concentrations, although to a
lesser extent than CC’s. Based on the absence of nicotine-concentration-related effects, it
could be argued that this is because the EC provides some of the cues associated with CC
smoking (e.g. tactile and visual similarity of the device, and similar inhalation behavior
compared to CC’s), which are conditioned reinforcers due to a history of these stimuli
being paired with nicotine delivered in CC’s. If this were the case these, this might
suggest that EC’s would have a lower abuse liability amongst individuals who have never
used CC’s. Yet, since this is the only study thus far to examine multiple nicotine
concentrations administered with the same device, further research should confirm these
findings before any firm conclusions are drawn.
There were significant changes seen in heart rate following smoking OB, but not
after smoking EC. This is commensurate with some previous research on EC’s
(Vansickel et al., 2010), yet inconsistent with other research (Vansickel, Weaver, and
Eissenberg, 2012; Vansickel and Eissenberg, 2012). Inconsistencies among studies with
regards to heart rate changes following using EC’s might reflect variations in nicotine
concentrations. Exemplifying this, Yan and D’Ruiz (2015) found that heart rate
significantly increased following ad-lib use of a Blu® EC with 24 mg/ml nicotine
concentration, while there was no significant change in heart rate following use of a Blu®
EC with 16 mg/ml nicotine concentration. Furthermore, Yan and D’Ruiz (2015) found a
positive correlation between plasma nicotine concentration and change in heart rate from
before to after EC use. This corroborates prior research, which has shown increases in
heart rate following administration of nicotine via multiple routes of administration (e.g.
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Benowitz et al., 1982; Henningfield, Miyasato, and Jasinski, 1985; Parrott and Winder,
1989).
The lack of ability of EC’s to alleviate withdrawal symptoms and reduced abuse
liability compared to CC’s in this study, in conjunction with the absence of heart rate
effects following use of an EC, might suggest a lack of significant nicotine delivery. This
would be congruent with a previous study that did not find significant elevations in
plasma nicotine levels following 20-puffs from a first-generation EC with 16 or 18 mg/ml
nicotine concentrations in a sample of EC naïve regular CC smokers (Vansickel et al.,
2010). Vansickel and colleagues (2010) speculated that naivety to EC use might
contribute to a lack of sufficient nicotine delivery. This speculation was supported by a
follow-up study by this group that demonstrated effective nicotine delivery in EC naïve
CC smokers following four 10-puff bouts from a first-generation EC with 16 mg/ml
nicotine concentration (Vansickel, Weaver, and Eissenberg, 2012). Based on those
findings, a comparable paced practice puffing procedure was incorporated into the design
of the current study to increase the likelihood that participants would be sufficiently
practiced to effectively use the EC. These procedures would be expected to enhance the
functional efficacy of EC’s relative to what would be encountered by smokers during
initial exposure to EC’s in the natural ecology. However, despite replicating the
procedures demonstrated to be effective in the Vansickel et al (2012) study, the current
study may not have been successful in training effective use of an EC, and insufficient
levels of nicotine may have been delivered at even the highest nicotine concentration (16
mg/ml) tested. In light of this possibility, future research on EC’s may want to
incorporate procedures designed to verify nicotine delivery.
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Limitations and Future Directions
There are several limitations to the current study that must be acknowledged.
First, although the device used in this study was chosen based on its popularity and wide
availability, results taken from this device may not generalize to other brands or types
(e.g. second- or third-generation) of EC’s. Second, this study examined EC’s in
individuals with minimal past EC experience. This was done in order to examine
processes associated with initial use of an EC among regular CC smokers. Nonetheless,
the effects reported in the current study may change as an individual gains more
experience with an EC, as suggested by studies demonstrating that regular EC users are
able to deliver behaviorally active nicotine doses (e.g. Yan and D’Ruiz, 2015). Third, a
paced puffing procedure was used in order to increase the likelihood of functional use of
the EC among study participants. Yet, it could be that more puffs are necessary to
effectively deliver nicotine to the user (suggested by Vansickel, Weaver, and Eissenberg,
2012). Lastly, there may be individual differences that contribute to vulnerability to EC
abuse liability, and by including subjects with prior but not current EC use individuals
who were low in vulnerability to EC abuse may have been over-represented in this
sample.
Conclusion
The current study demonstrated that, within the limitations of the nicotine
concentrations that were tested and number of puffs administered, first-generation EC’s
have no measurable efficacy in ameliorating tobacco withdrawal symptoms in regular CC
smokers and are definitely not as effective as tobacco cigarette smoking. Furthermore,
measures of abuse liability suggest that while EC’s may have some abuse liability under
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conditions of tobacco deprivation among regular tobacco smokers, the magnitude of the
liability is clearly lower than that of CC’s.
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